NDAORALCAPSULE
Approved
Sep 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
6/8 — Strong
COBENFY (xanomeline and trospium chloride) by Bristol Myers Squibb is cholinergic muscarinic agonists [moa]. First approved in 2024.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COBENFY is an oral capsule combining xanomeline and trospium chloride, approved by the FDA on September 26, 2024. It is a cholinergic muscarinic agonist indicated for schizophrenia and bipolar disorder. The dual mechanism enhances cholinergic signaling while mitigating anticholinergic side effects through trospium's antagonism.
Growth13.4 years to LOE
Recent 2024 approval positions COBENFY as a growth-stage asset with expanding commercial infrastructure; expect staffing growth in field sales, account management, and medical affairs roles over the next 2–3 years.
Mechanism of Action
Cholinergic Muscarinic Agonists
Pharmacologic Class:
Cholinergic Muscarinic Agonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia
Started Jul 2026
12 enrolled
SCHIZOPHRENIA 1 (Disorder)Schizoaffecitve Disorder
Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
Started Feb 2026
1,500 enrolled
Schizophrenia
Why This Matters for Your Career
Worked on COBENFY at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.